Table 4.13
Cancer of the Female Breast (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			TAT	White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+	
5-Year Relative Surviva	l (Percent)									
Year of Diagnosis:										
1960-1963ª	_	_	-	63	_	_	46	_	_	
1970-1973ª	_	-	-	68	-	-	51	_	-	
1975-1977 ^b	74.8	76.5	74.3	75.6	77.8	74.9	62.2	62.4	62.0	
1978-1980 ^b	74.4	75.5	74.1	75.1	76.1	74.9	63.4	67.0	61.5	
1981-1983 ^b	76.1	77.4	75.7	77.1	78.5	76.7	63.4	65.1	62.6	
1984-1986 ^b	78.9	77.8	79.3	80.0	79.5	80.2	65.1	63.9	65.9	
1987-1989 ^b	84.0	81.4	85.0	85.1	82.7	85.9	71.1	69.7	72.0	
1990-1992 ^b	85.2	83.4	85.9	86.5	85.1	87.0	71.5	70.1	72.3	
1993-1995 ^b	86.4	84.3	87.1	87.7	86.2	88.1	72.8	70.1	74.1	
1996-1998 ^b	88.2	86.6	88.8	89.4	88.3	89.7	76.3	74.0	77.6	
1990-1990 1999-2001 ^b	89.7	88.1	90.3	90.8		91.1	78.9		80.1	
					89.9			76.9		
2002-2004 ^b	90.0	89.3	90.2	91.4	91.1	91.5	77.9	77.6	78.2	
2005-2007 ^b	90.8	91.3	90.7	92.3	92.7	92.1	79.5	81.5	78.5	
2008-2014 ^b	91.1 ^f	91.0 ^f	91.1 ^f	92.1 ^f	92.2 ^f	92.1 ^f	83.1 ^f	83.5 ^f	82.9 ^f	
5	(D .) Cd									
5-Year Period Survival							0.4			
2014	89.7	89.4	89.9	90.7	90.6	90.7	81.4	80.9	81.6	
Stage Distribution (%)	2000_2014 ^{ce}									
	2008-2014									
All Stages	242 065	70 100	064 700	071 600	FO 10F	010 400	20 617	10 (52	07 064	
Number of cases	343,965	79,183	264,782	271,628	58,195	213,433	38,617	10,653	27,964	
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%	
Localized	62	54	64	63	55	65	54	47	57	
Regional	31	39	28	30	39	27	36	43	33	
Distant	6	5	6	6	5	6	9	8	9	
Unstaged/Unknown	2	1	2	1	1	2	2	2	2	
E Wasse Ballations (Consider)	1 (D	000 00145								
5-Year Relative Surviva	I (Percent), 2	008-2014								
Age at Diagnosis:	00.0			00 5			E0 1			
Ages <45_	88.2	_	-	89.5	-	_	79.1	-	-	
Ages 45-54	90.5	_	-	91.6	-	_	82.1	-	-	
Ages 55-64	90.3	_	=	91.3	-	=	82.2	-	-	
Ages 65-74	91.7	_	-	92.4	_	-	84.6	_	-	
Ages 75+	86.0	-	-	87.0	-	-	74.5	-	-	
Ages <65	89.9	_	-	91.1	-	-	81.4	-	_	
Ages 65+	89.3	-	-	90.0	_	_	80.6	-	_	
Stage ^e :										
All Stages	89.7	89.6	89.7	90.6	90.7	90.6	81.2	80.9	81.3	
Localized	98.7	97.0	99.2	99.1	97.4	99.6	95.4	94.0	95.9	
Regional	85.3	86.8	84.6	86.4	88.1	85.8	76.6	77.6	76.0	
Distant	27.0	37.3	24.1	28.1	40.3	25.2	19.7	27.0	17.0	
Unstaged/Unknown	54.5	75.8	49.6	52.1	75.8	47.6	49.8	67.1	43.5	
In Situ ^j	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	100.0	

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2015. Expected survival rates are derived from the U.S. Annual Life Tables.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2015.

Period survival provides a 2014 estimate of survival by piecing together the most recent conditional survival estimates

from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),

^{(2009-2011: 1-2} year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival). Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

The difference between 1975-1977 and 2008-2014 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

In situ cases are not included in the All Stages group.

Statistic could not be calculated due to fewer than 25 cases during the time period.